electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
electroCore, Inc. (Nasdaq: ECOR) announced a study demonstrating that non-invasive vagus nerve stimulation (nVNS) can enhance second language learning. The study, conducted at the Defense Language Institute, will be presented at the 2023 American Academy of Neurology Annual Scientific Meeting on April 23, 2023, in Boston. The poster details the ability of nVNS to accelerate vocabulary acquisition while also reducing fatigue and boosting focus. This development could broaden the commercial applications of electroCore's nVNS technology in educational settings and wellness markets, aligning with the company’s goal to leverage its platform for diverse health improvements.
- Study shows nVNS enhances second language vocabulary acquisition.
- Potential for new revenue streams in educational and wellness markets.
- Presentation at a prominent scientific meeting increases visibility.
- Actual market impact of nVNS for language learning remains uncertain.
- Funding challenges may impede further product development.
Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second Language
ROCKAWAY, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that data from a sham controlled study on the ability of nVNS to Accelerate Second Language Learning, conducted at the Defense Language Institute in Monterey, California, will be presented at the 2023 American Academy of Neurology Annual Scientific Meeting on April 23, 2023 in Boston, Massachusetts.
| Poster Presentation Details: | |
| Title: | Transcutaneous Cervical Vagus Nerve Stimulation Enhances Second Language Vocabulary Acquisition While Simultaneously Mitigating Fatigue and Promoting Focus |
| Date: | Sunday, April 23, 2023 |
| Time: | 11:45 a.m. – 12:45 p.m. ET |
| Presenter: | Toshiya Miyatsu, Ph.D. |
| Details: | Poster Session 2; P2.12-002 |
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans (including with respect to ongoing studies); its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models and revenue streams from the company’s potential use of nVNS for the enhancement of second learning vocabulary acquisition, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
FAQ
What is electroCore's recent study about?
When will electroCore present its research findings?
What technology does electroCore utilize for second language learning?
What are potential applications of electroCore's nVNS technology?
How might electroCore's findings impact its stock (ECOR)?
